Drug intelligence / Profile preview

PTT-019

Development stage: Preclinical
Lead developer: Pyrotech Therapeutics

Overview

PTT-019 is an investigational drug candidate being developed by Pyrotech Therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS). As of early 2024, the asset is in the early discovery phase of development. While specific molecular targets and mechanisms of action have not been publicly disclosed, the drug is categorized within Pyrotech's neuronal disorder pipeline. Pyrotech Therapeutics focuses on leveraging insights into innate immunity and neuroinflammation to develop therapies for inflammatory and neurodegenerative diseases.

Beyond the preview

Go deeper on PTT-019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTT-019.

Explore the full profile